Gene Solutions Expands Oncology Portfolio in Türkiye with ATC Genomics

Antalya, Türkiye – March 4, 2026 – Gene Solutions announced its strategic entry into the Turkish market, showcasing its comprehensive ctDNA-powered oncology portfolio at the 2nd International Hereditary Cancers Congress (IHCC), held February 5–8, 2026, in Antalya. The collaboration with ATC Genomics Sağlık Teknolojileri A.Ş. (ATC Genomics) aims to improve cancer care through advanced liquid biopsy technologies.

Advancing Precision Oncology in Türkiye

The IHCC, organized by the Hereditary Cancer Association, brought together over 600 medical oncologists, surgical oncologists, clinical geneticists, and laboratory directors to discuss evidence-based approaches to hereditary cancer prevention and precision oncology [1]. Gene Solutions and ATC Genomics co-hosted an industry satellite symposium, “ctDNA Across the Cancer Care Continuum – From Screening to Precision Care: Insights for High-Risk and Hereditary Populations,” exploring the potential of ctDNA and AI-powered multi-omics in cancer management [1].

Key Technologies Presented

Gene Solutions presented two core technologies:

• SPOT-MAS™: An AI-powered Multi-Cancer Early Detection (MCED) test designed to transform screening across Asia. It utilizes a multi-omics approach integrating genetic, epigenetic, and fragmentomic signatures from a single blood draw to detect 10 cancer types and 75 subtypes [1].
• K-4CARE™: A Comprehensive Genomic and Transcriptomic Profiling (CGTP) platform with longitudinal minimal residual disease (MRD) monitoring [1].

Real-World Evidence and Clinical Validation

Gene Solutions presented real-world evidence from one of the largest Asian cohorts evaluating its MCED assay, including data from 12,281 individuals [2]. The K-DETEK prospective study, involving 9,024 asymptomatic individuals, demonstrated 78.1% sensitivity and 99.8% specificity, with 84% AI-driven tissue-of-origin accuracy [1].

Expert Perspectives and Symposium Highlights

The symposium featured presentations from leading experts, including:

• Dr. Le Son Tran (Gene Solutions): Presented on SPOT-MAS and its multi-omics approach to cancer detection.
• Dr. Duy Sinh Nguyen (Gene Solutions): Introduced the K-4CARE platform for comprehensive genomic and transcriptomic profiling and MRD monitoring.
• Dr. Terence Aik Huang Tan (International Cancer Specialists, Singapore): Discussed the current clinical practice and future directions of ctDNA-MRD monitoring.

Professors Mustafa Özdoğan and Taha Bahşi of Memorial Health Group, Türkiye, co-chaired the symposium, focusing on the application of ctDNA across the cancer care continuum [1].

Strategic Partnership and Future Outlook

“Türkiye serves as a strategic gateway for precision oncology across Europe, Central Asia, the Middle East and Africa,” said Dr. Özgüncem Bozkulak, General Manager, TR-EEMEA-CIS, Gene Solutions [2]. Burcu Torun, Managing Partner and General Manager, ATC Genomics, added, “We are proud to partner with Gene Solutions to expand access to state-of-the-art liquid biopsy technologies in Türkiye.” [2]

Gene Solutions and ATC Genomics aim to provide accessible, clinically validated ctDNA solutions for early detection, treatment decision-making, and surveillance in Türkiye and beyond.